

Anthony Culyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6652753/publications.pdf>

Version: 2024-02-01

48
papers

1,743
citations

394421

19
h-index

289244

40
g-index

50
all docs

50
docs citations

50
times ranked

2101
citing authors

#	ARTICLE	IF	CITATIONS
1	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.5	8
2	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. Value in Health, 2022, 25, 869-886.	0.3	11
3	Reinforcing Science and Policy, With Suggestions for Future Research; Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design â€" Part II: A Practical Guide". International Journal of Health Policy and Management, 2022, , .	0.9	0
4	Distributional Cost-Effectiveness Analysis Comes of Age. Value in Health, 2021, 24, 118-120.	0.3	44
5	Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK. Health Economics, Policy and Law, 2021, 16, 489-504.	1.8	0
6	Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making. Cost Effectiveness and Resource Allocation, 2021, 19, 62.	1.5	14
7	A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain. Value in Health, 2021, 24, 1423-1434.	0.3	11
8	Building Capacity for Evidence-Informed Priority Setting in the Indian Health System: An International Collaborative Experience. Health Policy OPEN, 2020, 1, 100004.	1.5	7
9	Disability and multidimensional quality of life: A capability approach to health status assessment. Health Economics (United Kingdom), 2020, 29, 748-765.	1.7	5
10	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ, The, 2020, 368, m141.	6.0	25
11	Use of Evidence-Informed Deliberative Processes â€" Learning by Doing Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe". International Journal of Health Policy and Management, 2020, 9, 263-265.	0.9	6
12	Charging for the use of survey instruments on population health: the case of quality-adjusted life years. Bulletin of the World Health Organization, 2020, 98, 59-65.	3.3	3
13	What next after GDP-based cost-effectiveness thresholds?. Gates Open Research, 2020, 4, 176.	1.1	36
14	Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?. Value in Health, 2019, 22, 99-103.	0.3	20
15	How concentrated are academic publications of countries' progression towards universal health coverage?. The Lancet Global Health, 2019, 7, e696-e697.	6.3	1
16	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 2019, 19, 65-74.	1.2	11
17	National Institute for Health and Care Excellence, social values and healthcare priority setting. Journal of the Royal Society of Medicine, 2019, 112, 173-179.	2.0	19
18	How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations. Social Science and Medicine, 2019, 220, 141-149.	3.8	30

#	ARTICLE	IF	CITATIONS
19	Authors' Reply to Angelis and Kanavos: "Does MCDA Trump CEA?". Applied Health Economics and Health Policy, 2019, 17, 125-125.	2.1	0
20	9. Deliberative Processes in Decisions about Best Buys, Wasted Buys, and Contestable Buys. , 2019, , 147-170.		1
21	Expanding HTA " Correcting a Misattribution, Clarifying the Scope of HTA and CEA Comment on "Ethics in HTA: Examining the "Need for Expansion". International Journal of Health Policy and Management, 2019, 8, 732-733.	0.9	0
22	How can we make better health decisions: a Best Buy for all?. Gates Open Research, 2019, 3, 1543.	1.1	5
23	A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making. Value in Health, 2018, 21, 117-118.	0.3	10
24	Does MCDA Trump CEA?. Applied Health Economics and Health Policy, 2018, 16, 147-151.	2.1	17
25	Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?. F1000Research, 2018, 7, 72.	1.6	13
26	Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in Health, 2017, 20, 206-212.	0.3	181
27	Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research. F1000Research, 2017, 6, 231.	1.6	35
28	Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness". International Journal of Health Policy and Management, 2017, 6, 233-236.	0.9	28
29	We need a NICE for global development spending. F1000Research, 2017, 6, 1223.	1.6	1
30	Making Choices on the Journey to Universal Health Care Coverage: From Advocacy to Analysis. Value in Health, 2016, 19, 910-912.	0.3	2
31	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health, 2016, 19, 921-928.	0.3	203
32	Cost-effectiveness thresholds: a comment on the commentaries. Health Economics, Policy and Law, 2016, 11, 445-447.	1.8	0
33	Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Economics, Policy and Law, 2016, 11, 415-432.	1.8	76
34	HTA " Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy". International Journal of Health Policy and Management, 2016, 5, 501-505.	0.9	10
35	Priority-setting for achieving universal health coverage. Bulletin of the World Health Organization, 2016, 94, 462-467.	3.3	108
36	FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 236-240.	0.5	28

#	ARTICLE	IF	CITATIONS
37	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. Health Economics (United Kingdom), 2015, 24, 1-7.	1.7	88
38	National Health Insurance in South Africa: Relevance of a national priority-setting agency. South African Medical Journal, 2015, 105, 739.	0.6	10
39	Hic Sunt Dracones. Medical Decision Making, 2012, 32, E25-E32.	2.4	8
40	An Equity Framework for Health Technology Assessments. Medical Decision Making, 2012, 32, 428-441.	2.4	46
41	Perspective and Desire in Comparative Effectiveness Research. Pharmacoeconomics, 2010, 28, 889-897.	3.3	11
42	Welfarism vs. extra-welfarism. Journal of Health Economics, 2008, 27, 325-338.	2.7	260
43	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 2007, 12, 56-58.	1.7	155
44	Equity of What in Healthcare? Why the Traditional Answers Don't Help Policy - and What to Do in the Future. HealthcarePapers, 2007, 8, 12-26.	0.3	14
45	Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know?. Evidence and Policy, 2006, 2, 357-371.	1.0	98
46	NICE's use of cost effectiveness as an exemplar of a deliberative process. Health Economics, Policy and Law, 2006, 1, 299-318.	1.8	39
47	Involving Stakeholders in Healthcare Decisions - The Experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales. Healthcare Quarterly, 2005, 8, 56-60.	0.7	38
48	How can we make better health decisions a Best Buy for all?. Gates Open Research, 0, 3, 1543.	1.1	2